Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Immix Biopharma Inc (IMMX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$7.20-9.66%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for IMMX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Control net losses and cash burn | A primary condition in Immix Biopharma Inc's published investment case. The stated target is Net losses not to exceed -$10.1M per quarter. | Under Pressure | Net losses worsen beyond -$10.1M per quarter | Net income: $-11.557M FY2026-Q2; GAAP. Published target: Net losses not to exceed -$10.1M per quarter. The stored target says 2026-Q4; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 7, 2026-11,557,002 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 6, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotechnology business, not a proven earnings compounder. Its multi-year thesis is in a watch state, with low overall evidence confidence and a high-risk profile.
The snapshot gives no valuation level or expectations estimate, so it does not support a view on whether IMMX is cheap or expensive versus peers or what the market already assumes. No priced-in fragility gates have fired, but that does not resolve the uncertainty around the business.
Near term, trial progress offers some support: management reported positive interim NEXICART-2 results in Q3 2026 and expects topline results in Q3 2026, followed by a planned mid-2027 final readout and BLA submission. Loss control remains weak, and the $125 million stock offering supports development and working capital through mid-2028 while adding shares; the next results also carry elevated miss risk.
The multi-year thesis hinges on NEXICART-2 progress and whether the planned readout and submission milestones are achieved. Near term, a guidance cut or continued deterioration in jobs data could add pressure, while strong results and guidance from sector peers could support the healthcare backdrop.
Over the next 1 to 3 years, IMMX's case depends on clinical execution and funding runway, while persistent losses and near-term reporting risk keep the evidence mixed. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in a supplied disclosure. Management reported: “Immix intends to use the net proceeds from this offering to fund NXC-201 development, working capital and general corporate purposes.”
Delivery assessment Nov 4, 2026Advance NEXICART-2 trial with topline results in Q3 2026 | Immix Biopharma is advancing its key NEXICART-2 trial with topline results expected in Q3 2026. | Intact | Topline results not reported by Q3 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in a supplied disclosure. Management reported: “NEXICART-2 final readout and BLA submission are planned in 2027.” “We look forward to final readout, BLA submission and potentially making NXC-201 available to relapsed/refractory AL Amyloidosis patients at commercial launch.”” Delivery assessment Nov 4, 2026 |
Begin revenue generation from commercial launch | The company plans a BLA submission and commercial launch thereafter. | Intact | Revenue falls below $45M in FY 2027 | Revenue: $0 FY2026-Q2; GAAP. Published target: Revenue >= $45M in FY 2027. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Aug 7, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in a supplied disclosure. Management reported: “NEXICART-2 final readout and BLA submission are planned in 2027.” “We look forward to final readout, BLA submission and potentially making NXC-201 available to relapsed/refractory AL Amyloidosis patients at commercial launch.”” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.74 → $-0.95 · observed estimates
$0.04B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.74 | $37,610,957 | 5 / 4 |
| 2026-07-25 | $-0.74 | $37,610,957 | 5 / 4 |
| 2026-07-26 | $-0.84 | $32,237,963 | 5 / 4 |
| 2026-07-27 | $-0.84 | $32,237,963 | 5 / 4 |
| 2026-07-28 | $-0.84 | $32,237,963 | 5 / 4 |
| 2026-07-29 | $-0.84 | $32,237,963 | 5 / 4 |
| 2026-07-30 | $-0.84 | $32,237,963 | 5 / 4 |
| 2026-07-31 | $-0.84 | $37,610,960 | 7 / 6 |
| 2026-08-01 | $-0.84 | $32,237,963 | 5 / 4 |
| 2026-08-02 | $-0.84 | $37,610,960 | 7 / 6 |
| 2026-08-03 | $-0.84 | $32,237,963 | 5 / 4 |
| 2026-08-04 | $-0.84 | $37,610,960 | 7 / 6 |
| 2026-08-05 | $-0.84 | $37,610,960 | 7 / 6 |
| 2026-08-06 | $-0.84 | $37,610,960 | 7 / 6 |
| 2026-08-07 | $-0.84 | $32,237,963 | 5 / 4 |
| 2026-08-08 | $-0.84 | $37,610,960 | 7 / 6 |
| 2026-08-09 | $-0.84 | $37,610,960 | 7 / 6 |
| 2026-08-10 | $-0.84 | $37,610,960 | 7 / 6 |
| 2026-08-12 | $-0.84 | $32,237,963 | 5 / 4 |
| 2026-08-13 | $-0.84 | $32,237,963 | 5 / 4 |
| 2026-08-14 | $-0.84 | $32,237,963 | 5 / 4 |
| 2026-08-15 | $-0.84 | $32,237,963 | 6 / 5 |
| 2026-08-16 | $-0.84 | $32,237,963 | 6 / 5 |
| 2026-08-17 | $-0.84 | $32,237,963 | 6 / 5 |
| 2026-08-18 | $-0.84 | $32,237,963 | 6 / 4 |
| 2026-08-19 | $-0.84 | $32,237,963 | 6 / 5 |
| 2026-08-20 | $-0.90 | $23,101,468 | 6 / 5 |
| 2026-08-21 | $-0.90 | $23,101,468 | 6 / 5 |
| 2026-08-22 | $-0.90 | $23,101,468 | 6 / 5 |
| 2026-08-23 | $-0.90 | $23,101,468 | 6 / 5 |
| 2026-08-24 | $-0.90 | $23,101,468 | 6 / 5 |
| 2026-08-25 | $-0.90 | $23,101,468 | 6 / 5 |
| 2026-08-26 | $-0.90 | $23,101,468 | 6 / 5 |
| 2026-08-27 | $-0.90 | $23,101,468 | 6 / 5 |
| 2026-08-28 | $-0.90 | $23,101,468 | 6 / 5 |
| 2026-08-29 | $-0.90 | $23,101,468 | 6 / 5 |
| 2026-08-30 | $-0.90 | $23,101,468 | 6 / 5 |
| 2026-08-31 | $-0.90 | $23,101,468 | 6 / 5 |
| 2026-09-01 | $-0.90 | $23,101,468 | 6 / 5 |
| 2026-09-02 | $-0.90 | $23,101,468 | 6 / 5 |
| 2026-09-03 | $-0.90 | $23,101,468 | 6 / 5 |
| 2026-09-04 | $-0.90 | $23,101,468 | 6 / 5 |
| 2026-09-05 | $-0.91 | $23,101,468 | 6 / 5 |
| 2026-09-06 | $-0.91 | $23,101,468 | 6 / 5 |
| 2026-09-07 | $-0.91 | $23,101,468 | 6 / 5 |
| 2026-09-08 | $-0.91 | $23,101,468 | 6 / 5 |
| 2026-09-09 | $-0.91 | $23,101,468 | 6 / 5 |
| 2026-09-10 | $-0.91 | $23,101,468 | 6 / 5 |
| 2026-09-11 | $-0.91 | $23,101,468 | 6 / 5 |
| 2026-09-12 | $-0.91 | $23,101,468 | 6 / 5 |
| 2026-09-13 | $-0.91 | $23,101,468 | 6 / 5 |
| 2026-09-14 | $-0.91 | $23,101,468 | 6 / 5 |
| 2026-09-15 | $-0.91 | $23,101,468 | 6 / 5 |
| 2026-09-16 | $-0.86 | $23,101,468 | 6 / 5 |
| 2026-09-17 | $-0.86 | $23,101,468 | 6 / 5 |
| 2026-09-18 | $-0.86 | $23,101,468 | 6 / 5 |
| 2026-09-19 | $-0.86 | $23,101,468 | 6 / 5 |
| 2026-09-20 | $-0.86 | $23,101,468 | 6 / 4 |
| 2026-09-21 | $-0.86 | $23,101,468 | 6 / 4 |
| 2026-09-22 | $-0.86 | $23,101,468 | 6 / 4 |
| 2026-09-23 | $-0.86 | $23,101,468 | 6 / 4 |
| 2026-09-24 | $-0.86 | $23,101,468 | 6 / 4 |
| 2026-09-25 | $-0.86 | $26,401,678 | 6 / 4 |
| 2026-09-26 | $-0.86 | $26,401,678 | 6 / 4 |
| 2026-09-27 | $-0.86 | $26,401,678 | 6 / 4 |
| 2026-09-28 | $-0.86 | $26,401,678 | 6 / 4 |
| 2026-09-29 | $-0.86 | $26,401,678 | 6 / 4 |
| 2026-09-30 | $-0.86 | $26,401,678 | 6 / 4 |
| 2026-10-01 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-02 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-03 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-04 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-05 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-06 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-07 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-08 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-09 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-10 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-11 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-12 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-13 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-14 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-15 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-16 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-17 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-18 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-19 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-20 | $-0.85 | $26,401,678 | 6 / 4 |
| 2026-10-21 | $-0.95 | $26,401,678 | 6 / 4 |
| 2026-10-22 | $-0.95 | $26,401,678 | 6 / 4 |
| 2026-10-23 | $-0.95 | $26,401,678 | 6 / 4 |
| 2026-10-24 | $-0.95 | $26,401,678 | 6 / 4 |
| 2026-10-25 | $-0.95 | $26,401,678 | 6 / 4 |
| 2026-10-26 | $-0.95 | $26,401,678 | 6 / 4 |
| 2026-10-27 | $-0.95 | $26,401,678 | 6 / 4 |
| 2026-10-28 | $-0.95 | $26,401,678 | 6 / 4 |
| 2026-10-29 | $-0.95 | $26,401,678 | 6 / 4 |
| 2026-10-30 | $-0.95 | $26,401,678 | 6 / 4 |
| 2026-10-31 | $-0.95 | $26,401,678 | 6 / 4 |
| 2026-11-01 | $-0.95 | $26,401,678 | 6 / 4 |
| 2026-11-02 | $-0.95 | $26,401,678 | 6 / 4 |
| 2026-11-03 | $-0.95 | $26,401,678 | 6 / 4 |
| 2026-11-04 | $-0.95 | $26,401,678 | 6 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
1 raises · 1 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.